Evidence map›Paper›PMID 35610285›Full record

ArticleScientific reports2022

Lab-on-chip assay of tumour markers and human papilloma virus for cervical cancer detection at the point-of-care.

Benjamin W Wormald, Nicolas Moser, Nandita M deSouza, Katerina-Theresa Mantikas, Kenny Malpartida-Cardenas, Ivana Pennisi, Thomas E J Ind, Katherine Vroobel, Melpomeni Kalofonou, Jesus Rodriguez-Manzano and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. The Future of Cervical Cancer Screening.International journal of women's health · 2024
    Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Benjamin W WormaldCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SW7 3RP, UK.
Nicolas MoserCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, SW7 2BT, UK.
Nandita M deSouzaCancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SW7 3RP, UK.
Katerina-Theresa MantikasCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, SW7 2BT, UK.
Kenny Malpartida-CardenasCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, SW7 2BT, UK.
Ivana PennisiDepartment of Infectious Disease, Imperial College London, School of Medicine, St Mary's Hospital, London, W2 1NY, UK.
Thomas E J IndDepartment of Surgical Oncology, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
Katherine VroobelDepartment of Pathology, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK.
Melpomeni KalofonouCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, SW7 2BT, UK.
Jesus Rodriguez-ManzanoDepartment of Infectious Disease, Imperial College London, School of Medicine, St Mary's Hospital, London, W2 1NY, UK.
Pantelis GeorgiouCentre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, London, SW7 2BT, UK. pantelis@imperial.ac.uk.
Imperial College London · GBInstitute of Cancer Research · GBRoyal Marsden NHS Foundation Trust · GBSt Mary's Hospital · GB

Funding

Cancer Research UK 16464Cancer Research UK C309/A26234Department of Health
6 · The paper itself

Abstract

Cervical cancer affects over half a million people worldwide each year, the majority of whom are in resource-limited settings where cytology screening is not available. As persistent human papilloma virus (HPV) infections are a key causative factor, detection of HPV strains now complements cytology where screening services exist. This work demonstrates the efficacy of a handheld Lab-on-Chip (LoC) device, with an external sample extraction process, in detecting cervical cancer from biopsy samples. The device is based on Ion-Sensitive Field-Effect Transistor (ISFET) sensors used in combination with loop-mediated isothermal amplification (LAMP) assays, to amplify HPV DNA and human telomerase reverse transcriptase (hTERT) mRNA. These markers were selected because of their high levels of expression in cervical cancer cells, but low to nil expression in normal cervical tissue. The achieved analytical sensitivity for the molecular targets resolved down to a single copy per reaction for the mRNA markers, achieving a limit of detection of 10

Indexed as

AlphapapillomavirusPapillomavirus InfectionsTelomeraseUterine Cervical NeoplasmsBiomarkers, TumorEarly Detection of CancerFemaleHumansPapillomaviridaePoint-of-Care SystemsRNA, MessengerBiomarkers, TumorRNA, MessengerTelomerase

Identifiers

PMID35610285
PMCPMC9128326
OpenAlexW4281396730

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.